ARS Pharmaceuticals Inc (NASDAQ:SPRY) price on current trading day, rose 28.53% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $14.97.
A look at the stock’s price movement, the level at last check in today’s session was $11.65, moving within a range at $12.281 and $15.0868. The beta value (5-Year monthly) was 1.411. Turning to its 52-week performance, $18.51 and $7.55 were the 52-week high and 52-week low respectively. Overall, SPRY moved 24.78% over the past month.
ARS Pharmaceuticals Inc’s market cap currently stands at around $1.46 billion, with investors looking forward to this quarter’s earnings report slated for on 2024-Nov-12.
Analysts have a consensus estimate of 14M for the company’s revenue for the quarter, with a low and high estimate of 7.1M and 31M respectively. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 124.5M, representing a 39.65% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SPRY is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 4 recommend SPRY as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
SPRY’s current price about 33.20% and 24.60% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 74.55, while 7-day volatility ratio is 5.03% and 6.12% in the 30-day chart. Further, ARS Pharmaceuticals Inc (SPRY) has a beta value of 0.94, and an average true range (ATR) of 0.89. Analysts have given the company’s stock an average 52-week price target of $22, forecast between a low of $18 and high of $30. Looking at the price targets, the low is -20.24% off recent price level in today’s trading while to achieve the yearly target high, it has to move -100.4%. Nonetheless, investors will most likely welcome a -46.96% jump to $22 which is the analysts’ median price.
If we refocus on ARS Pharmaceuticals Inc (NASDAQ:SPRY), historical trading data shows that trading volumes averaged 1.22 over the past 10 days and 1.34 million over the past 3 months. The company’s latest data on shares outstanding shows there are 97.15 million shares.
The 47.22% of ARS Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 51.01% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 19.0 million on 2025-02-28, giving us a short ratio of 15.51. The data shows that as of 2025-02-28 short interest in ARS Pharmaceuticals Inc (SPRY) stood at 3676.0 of shares outstanding, with shares short rising to 14.67 million registered in 2025-01-31. Current price change has pushed the stock 41.93% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SPRY stock continues to rise going into the next quarter.
